$55.72
4.98% day before yesterday
Nasdaq, Jul 25, 10:00 pm CET
ISIN
US74276L1052
Symbol
PRCT

PROCEPT BioRobotics Stock price

$55.72
-2.50 4.29% 1M
-18.97 25.40% 6M
-24.80 30.80% YTD
-8.68 13.48% 1Y
+18.95 51.54% 3Y
+13.78 32.86% 5Y
+13.78 32.86% 10Y
+13.78 32.86% 20Y
Nasdaq, Closing price Fri, Jul 25 2025
-2.92 4.98%
ISIN
US74276L1052
Symbol
PRCT

Key metrics

Basic
Market capitalization
$3.1b
Enterprise Value
$2.8b
Net debt
positive
Cash
$316.2m
Shares outstanding
55.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
12.4 | 9.3
EV/Sales
11.3 | 8.5
EV/FCF
negative
P/B
7.9
Financial Health
Equity Ratio
75.3%
Return on Equity
-22.7%
ROCE
-20.6%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$249.1m | $330.9m
EBITDA
$-90.9m | $-40.1m
EBIT
$-96.4m | $-90.3m
Net Income
$-90.2m | $-85.1m
Free Cash Flow
$-88.2m
Growth (TTM | estimate)
Revenue
59.4% | 47.4%
EBITDA
12.8% | 56.1%
EBIT
11.1% | 6.5%
Net Income
12.8% | 6.9%
Free Cash Flow
30.1%
Margin (TTM | estimate)
Gross
62.7%
EBITDA
-36.5% | -12.1%
EBIT
-38.7%
Net
-36.2% | -25.7%
Free Cash Flow
-35.4%
More
EPS
$-1.6
FCF per Share
$-1.6
Short interest
14.6%
Employees
626
Rev per Employee
$360.0k
Show more

Is PROCEPT BioRobotics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

PROCEPT BioRobotics Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a PROCEPT BioRobotics forecast:

14x Buy
82%
3x Hold
18%

Analyst Opinions

17 Analysts have issued a PROCEPT BioRobotics forecast:

Buy
82%
Hold
18%

Financial data from PROCEPT BioRobotics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
249 249
59% 59%
100%
- Direct Costs 93 93
28% 28%
37%
156 156
87% 87%
63%
- Selling and Administrative Expenses 187 187
32% 32%
75%
- Research and Development Expense 66 66
29% 29%
26%
-91 -91
13% 13%
-36%
- Depreciation and Amortization 5.53 5.53
32% 32%
2%
EBIT (Operating Income) EBIT -96 -96
11% 11%
-39%
Net Profit -90 -90
13% 13%
-36%

In millions USD.

Don't miss a Thing! We will send you all news about PROCEPT BioRobotics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PROCEPT BioRobotics Stock News

Neutral
GlobeNewsWire
3 days ago
SAN JOSE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (“the Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that Larry L. Wood will join the Company as president and CEO effective September 2, 2025. Dr. Reza Zadno will retire as president, CEO, and director effective Sept...
Neutral
GlobeNewsWire
4 days ago
SAN JOSE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformative urology solutions, today announced that three prostate cancer procedures in the WATER IV Prostate Cancer (PCa) Trial were successfully completed in an Ambulatory Surgery Center (ASC) using Aqua...
Neutral
GlobeNewsWire
6 days ago
SAN JOSE, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2025 after market close on Wednesday, August 6, 2025. The Company's management will host a c...
More PROCEPT BioRobotics News

Company Profile

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in Redwood City, CA.

Head office United States
CEO Reza Zadno
Employees 626
Founded 2007
Website www.procept-biorobotics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today